The churn rate through most lupus medications supports other evidence that there is an unmet need for new therapies. That’s one of the take home messages from an analysis of medication use between 2013 and 2018 from the Asia Pacific Lupus Collaboration (APLC) cohort, presented recently at the EULAR 2020 e-Congress. The study described the ...
Low medication persistence rates in lupus show need for more effective therapies
By Mardi Chapman
15 Jun 2020